# Progress Note 04 — Sick Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mary McLeod Bethune (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML043-SYN-TD
- Date: 1948-06-15
- Fictional facility: St. Posthumous Health Center
- Fictional author: Viola Harrington-Mbeki, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Sick Visit
- Services: Problem-oriented office visit, established patient, with bronchodilator treatment and observation in clinic

## Chief complaint

Worsening wheeze and breathlessness for two days with a cold. **S**

## History of present illness

Mrs. Bethune called the clinic this morning from the yellow zone of her action plan and was seen the same day. Five days ago she developed a cold with a runny nose and sore throat after a crowded church gathering. For two days her wheeze and chest tightness have worsened; she woke three times last night and has needed eight extra inhalations of budesonide-formoterol in each of the last two days, as her plan allows. Her morning peak flow has fallen from about 300 to 210 L/min. She can speak in full sentences and has no chest pain. She has no fever, green sputum or leg swelling, and has had no ankle swelling or orthopnea that would suggest heart failure. She takes her maintenance inhalations with the spacer, amlodipine and atorvastatin as prescribed. She has never been admitted to hospital for asthma or needed a breathing tube. **S**

| Element | Detail |
|---|---|
| Onset | Cold five days ago; asthma worse for two days |
| Severity | Woke three times last night; eight reliever inhalations a day; morning peak flow 210 L/min |
| Context | Low-dose budesonide-formoterol maintenance and reliever; yellow zone of her action plan |
| Associated signs and symptoms | Runny nose and sore throat; no fever, chest pain, purulent sputum or leg swelling |
| Risk history | No previous admission, intensive care or intubation for asthma; no oral corticosteroid in the past year |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; temperature 37.4 °C; no rigors |
| Respiratory | Positive | Wheeze, chest tightness and night waking; dry cough; no hemoptysis |
| Ears, nose, mouth, and throat | Positive | Runny nose and sore throat |
| Cardiovascular | Negative | No chest pain, orthopnea or ankle swelling |

4 systems reviewed. **S**

## Current medications

- Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning for five days **S**
- Budesonide-formoterol 160/4.5 mcg inhaler with a spacer: two inhalations twice daily and one as needed (stepped up during the exacerbation), no more than 12 inhalations a day **S**
- Fluticasone propionate 50 mcg/actuation nasal spray, two sprays in each nostril once daily, aimed away from the septum **S**
- Sodium chloride 0.65% nasal spray, two sprays in each nostril up to four times daily before the steroid spray **S**
- Amlodipine 5 mg oral tablet, one tablet daily **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 138/82 mmHg; pulse 98 bpm; respirations 22/min; temperature 37.4 °C; oxygen saturation 94% on room air; weight 87.2 kg; BMI 32.8 kg/m². All vital signs are synthetic.

Peak expiratory flow: 205 L/min (low). All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Alert, sitting upright, speaking in full sentences; not using accessory muscles |
| Vital signs | Pulse 98, respiratory rate 22, oxygen saturation 94 percent on room air, temperature 37.4 °C; peak flow 205 L/min (60 percent of her best) |
| Head, eyes, ears, nose, and throat | Red throat; clear nasal discharge |
| Respiratory | Widespread expiratory wheeze with good air entry; no crackles |
| Cardiovascular | Regular rhythm; jugular venous pressure not raised; no edema |
| Reassessment after one hour | After albuterol 8 puffs by spacer three times over an hour: peak flow 275 L/min (81 percent), oxygen saturation 96 percent, pulse 92, wheeze much reduced |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Moderate asthma exacerbation triggered by a cold** (J45.41). A moderate exacerbation: peak flow 60 percent of her best, saturation 94 percent, speaking in full sentences, with a good response in clinic. Heart failure is unlikely: no orthopnea or edema and a normal jugular venous pressure, with normal pumping function and no raised filling pressures on the echocardiogram three months ago. Safe to go home with treatment and close follow-up; no antibiotic, because there are no signs of bacterial infection. **S**
   - Prednisone 40 mg each morning for five days.
   - Budesonide-formoterol maintenance increased to two inhalations twice daily, with one as needed, up to 12 a day in total.
   - Peak flow morning and evening; go to the emergency department or call 911 if peak flow falls below 170, she cannot speak in sentences, or her lips turn blue.
   - Nurse telephone calls in two and seven days; review in clinic within a week.
2. **Asthma** (J45.40). First exacerbation needing an oral corticosteroid since she started ICS-formoterol; a cold was the trigger. **S**
   - Action plan reviewed with her; it worked as intended.
   - Influenza, COVID-19 and RSV vaccines in the autumn.
3. **Hypertensive heart disease** (I11.9). Blood pressure 138/82 while unwell on albuterol. **S**
   - Continue amlodipine.

## Medication changes

- Started: Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning for five days **S**
- Stopped: Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a day **S**
- Started: Budesonide-formoterol 160/4.5 mcg inhaler with a spacer: two inhalations twice daily and one as needed (stepped up during the exacerbation), no more than 12 inhalations a day **S**

## Guideline basis

- Global Strategy for Asthma Management and Prevention, 2025 update (2025), Global Initiative for Asthma
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020), National Heart, Lung, and Blood Institute (J Allergy Clin Immunol 2020;146(6):1217-1270)

## Follow-up

- Nurse telephone calls in two and seven days. Clinic review within a week. Emergency care for any red-zone sign. **S**
- Next scheduled visit 1948-07-27: review six weeks after an exacerbation: control, repeat spirometry and FeNO, biologic assessment, blood pressure and the post-exacerbation plan. **S**
